A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms Liberty Asthma Quest
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Sep 2017 This trial has been completed in Spain.
    • 11 Sep 2017 Results published in a Sanofi media release.
    • 11 Sep 2017 Results presented in a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top